This funding opportunity supports exploratory and early-stage research projects that focus on undruggable target classes within intractable human diseases. Applicants are expected to develop innovative methods or agents selective for these targets, aiming to expand therapeutic options beyond established drug types. Clinical trials are not allowed under this R21 mechanism, emphasizing foundational research and method development.
Eligible applicants include a wide range of organizations such as public and private higher education institutions, tribal organizations, government entities, nonprofits, and for-profit organizations including small businesses. Specific eligibility details should be confirmed with the funding source
